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Moses J. Bockarie, Louise A. Kelly-Hope, Maria Rebollo
and David H. Molyneux
Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Pembroke Place,
Liverpool L3 5QA, UK
Global efforts to address neglected tropical diseases (NTDs) were stimulated
in January 2012 by the London declaration at which 22 partners, including
the Bill & Melinda Gates Foundation, World Bank, World Health Organiza-
tion (WHO) and major pharmaceutical companies committed to sustaining
and expanding NTD programmes to eliminate or eradicate 11 NTDs by 2020
to achieve the goals outlined in the recently published WHO road map.
Here, we present the current context of preventive chemotherapy for some
NTDs, and discuss the problems faced by programmes as they consider
the ‘endgame’, such as difficulties of access to populations in post-conflict set-
tings, limited human and financial resources, and the need to expand access to
clean water and improved sanitation for schistosomiasis and soil-transmitted
helminthiasis. In the case of onchocerciasis and lymphatic filariasis, ivermectin
treatment carries a significant risk owing to serious adverse effects in
some patients co-infected with the tropical eye worm Loa loa filariasis. We
discuss the challenges of managing complex partnerships, and maintain
advocacy messages for the continued support for elimination of these
preventable diseases.1. Introduction
The term preventive chemotherapy (PC) was introduced by the World Health
Organization (WHO) [1], to cover the approach of treating populations at risk
of human helminth diseases, to prevent transmission or morbidity of those dis-
eases, with drugs either alone or in combination. Delivery is usually undertaken
by mass drug distribution campaigns organized by national health services but
delivered by communities, through school-based treatments or via the health
services themselves. The funding for these drug distribution programmes
comes from a variety of sources, including endemic countries, bilateral
donors, international organization trust funds and non-governmental develop-
ment organizations (NGDOs). Increasingly, the strategy of PC is part of an
expanded integrated programme to address the neglected tropical diseases
(NTDs), including meeting targets for elimination or control [2], as delineated
by World Health Assembly (WHA) resolutions (see the electronic supplemen-
tary material, table S1).
The progress of programmes based on PC over the last decade has been
spectacular in terms of the numbers of people treated (now with over
700 million individual treatments annually), the increase in donations from
the pharmaceutical industry, and the recent bilateral commitments to integra-
ted NTD control/elimination programmes [3–5]. However, this progress
creates challenges as programmes seek to achieve targets of elimination or
reduced prevalence, incidence and morbidity [6]. This will be the focus of
this paper.
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preventive chemotherapy in control
and elimination
Collaborative work between pharmaceutical companies
contributing drugs and finances, the WHO [2,7], academic
institutions, NGDOs and endemic country governments
have produced the tools and strategies necessary to achieve
the goal of control or elimination of many NTDs, supported
by disease-specific partnerships or alliances ([2,7]; www.uni-
tingtocombatntds.org). The donation of ivermectin (as
Mectizan) for the control and now elimination of onchocercia-
sis in 1987 by Merck & Co. Inc. was a landmark in the history
of public health [8–10]. Ivermectin kills microfilaria in the
skin and inhibits their release by female worms, reducing
transmission of Onchocerca volvulus by Simulium vectors. To
interrupt transmission, a minimum of 15 years annual treat-
ment is required, the duration of life of adult worms.
Ivermectin has only limited impact on adult Onchocerca
worms, but relieves pruritus (itching) and delays the pro-
gression of ocular morbidity that can lead to irreversible
blindness, in addition to reducing transmission. Mobile
teams were initially deployed to distribute ivermectin in the
Onchocerciasis Control Programme (OCP) in West Africa as
a supplement to vector control in 1988. The effectiveness of
ivermectin as a microfilaricide led to the creation of the
African Programme for Onchocerciasis Control (APOC) in
1995 [11], targeting disease control in 19 endemic African
countries not included in the OCP. APOC’s success [12] has
been built on the development of community-directed
treatment with ivermectin, an approachwhich shifts responsi-
bility of drug delivery from the health system to distributors
selected by the community, who collect the drugs from the
health service and decide on the time they would distribute
drugs to their community. This is a sustainable approach,
with successful coverage maintained over periods as long as
20 years [13], a key issue in the context of the endgame. More
generally, community-directed intervention (CDI) can be
used to deliver other health needs [14], for example distribution
of bed nets and access to drugs for the home management of
malaria [15].
Various lines of evidence from onchocerciasis control
efforts indicate the potential for NTD elimination using PC
alone. The elimination of transmission of onchocerciasis has
been achieved in some foci in countries in the Americas
using ivermectin alone given twice yearly and more recently
four times per year to accelerate the process towards the end-
game. Initially, six countries had foci, and around 500 000
people were at risk. Treatment twice a year [16] interrupted
transmission first in the Santa Rosa focus in Guatemala [17]
and then in small foci in Colombia (Lopez de Micay) [18]
and Ecuador [19]. Subsequently, in the Escuintla–Guatemala
focus (which had higher transmission levels), transmission
was arrested after twice yearly treatment from 2002 to 2007
[20]. In most foci in the Americas, treatment has been stopped
and post-treatment surveillance is ongoing to detect recrudes-
cence. This success of elimination using ivermectin alone was
reproduced in the African setting in Mali and Senegal [21],
where after 15–17 years of treatment with ivermectin in
annual or six-month intervals, transmission had been effec-
tively eliminated in 126 previously hyperendemic villages,
which has been confirmed by entomological data. A studyin Nigeria [22], where initial baseline community prevalence
was between 23.1 and 84.9 per cent, reported zero prevalence
from two foci in Kaduna State (Birnin Gwari and Kauru/
Lere) after 15–17 years annual treatment with 75 per cent
coverage (still awaiting entomological confirmation).
Successes stemming from the original donation by Merck &
Co. Inc. of ivermectin inspired long-term commitments
from other major pharmaceutical companies for other
NTDs. Novartis donated curative treatments for leprosy,
following the demonstration of the efficacy of multidrug
therapy (rifampicin, dapsone and clofomazine). Glaxo-
SmithKline committed to providing albendazole for the
elimination of lymphatic filariasis in 1998, and Merck & Co.
Inc. expanded their donation of ivermectin for countries
co-endemic for onchocerciasis and lymphatic filariasis. This
is necessary because the second drug in the package of
annual treatment, diethylcarbamazine (DEC), cannot be
used in countries where onchocerciasis is endemic given the
risk of complications owing to Mazzoti reactions. These are
rapid onset, post-treatment reactions caused by the rapid
death of microfilaria parasites owing to inflammatory reac-
tions to both parasite antigens and Wolbachia [22,23]. The
benefit of ivermectin is that it kills microfilaria more slowly
and hence the reactions to microfilarial death are not as
severe as those with DEC, thus making ivermectin safer
and more acceptable, and is an important consideration for
community acceptability and sustainability in the context of
the endgame.
Another important helminthic parasite disease, schistoso-
miasis, caused by species of the genus Schistosoma, is
reportedly endemic in 78 countries worldwide [7,24,25]. Of
the estimated 240 million infections globally, over 200 million
occur in Africa although there are foci of Schistosoma mansoni
in Brazil and smaller countries in the Americas, and of
Schistosoma japonicum and Schistosoma mekongi in Asia.
Nineteen previously endemic countries have interrupted
transmission as a public health problem through a combina-
tion of drug treatment, improved sanitation and mollusciding
[7,25–28]. A cornerstone for the elimination of morbidity due
to schistosomiasis is praziquantel, essentially the only medi-
cine commercially available to treat human schistosomiasis
[2]. Despite the expansion in coverage of treatment of schisto-
somiasis with praziquantel from 12 million people in 2006 to
35 million people in 2011 [29] and increased support for
control, schistosomiasis remains a major public health pro-
blem [7]. The expansion of the treatment with praziquantel
continues, and by 2015 there will be sufficient doses to treat
100million people per year. Examples of successful elimination
maintain optimism, for example transmission in Egypt is now
restricted to local hotspots, so that Schistosomiasis haematobium-
induced bladder cancer has been dramatically reduced as a
cause of mortality, and prevalences of both S. haematobium
and S. mansoni have been reduced by some 80 per cent with
corresponding reductions in intensities of infection. China
has made significant progress in reducing morbidity of
S. japonicum [25]. Large-scale use of PC has likewise decreased
schistosomiasis transmission rates as evinced through reduced
environmental contamination by eggs discharged by infected
people [30], an impact even more evident with urogenital
schistosomiasis [31–33]. As a consequence of such patterns,
population-based treatment has increasingly been regarded
as a public health tool capable of decreasing and interrupting
transmission of infection.
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In January 2012, a group of partners, including the UK
Department for International Development (DFID), the United
States Agency for International Development (USAID), the
Bill & Melinda Gates Foundation, the WHO, the World Bank
and major pharmaceutical companies, made commitments to
sustain and expand NTD programmes to control or eliminate
10NTDsby 2020 (www.unitingtocombatntds.org). Thediversity
of the partners involved in each disease [7,34–36] and the
momentum required to integrate interventions against different
NTDs poses many challenges, including the coordination
and harmonization of drug application procedures, ensuring
the reporting of adverse events to comply with regula-
tory responsibilities and minimization of import taxes and
administrative hurdles to getting drugs to endemic countries.
The partners and alliances serve key roles in advocacy
and resource mobilization for NTDs. Inevitably, programmes
for elimination or control by PC at either global or regional
scales have historically proceeded at different rates driven
usually by resource availability and country commitment. The
timeline ordinarily includes an initial WHA resolution (see the
electronic supplementary material, table S1) or regional resol-
ution, for example for onchocerciasis in the Americas, the
development of a constituency of partners, the definition of the
problem through mapping of the disease burden, establishment
of financing options, development of drug management pro-
cesses, identification of implementing partners (e.g. ministries
of health and NGDOs), maintenance of implementation over
several years, undertaking evaluation and monitoring, and
finallypost-intervention surveillance andverification of interrup-
tion of transmission or absence of morbidity. These activities are
all essential components if the endgame is to be achieved.4. Implementation challenges
Current practices in the management of NTDs have been
influenced by the push for integrated control of the diseases
amenable to PC, together with the application of alternative
intervention strategies to accelerate the interruption of trans-
mission. Additional intervention strategies recommended in
the 2012 WHO roadmap for implementation also include
vector control, provision of safe water and improved
sanitation and hygiene. Amazigo et al. [37] identified 11
major challenges following the experiences of the APOC pro-
gramme (which focused on sustainable delivery of ivermectin
as an objective at that time rather than elimination, but are
generally applicable):
(1) maintaining timely drug distribution;
(2) integrating distribution into existing primary healthcare
services;
(3) strengthening local health infrastructure;
(4) achieving and maintaining optimal coverage;
(5) establishing and up scaling self monitoring by
communities;
(6) implementing operational research;
(7) ensuring adequacy of community distributors;
(8) increasing involvement of local NGDOs;
(9) achieving financial sustainability;
(10) implementing equitable cost recovery systems; and
(11) engaging in effective advocacy.Kyelem et al. [38] analysed data from eight countries and
identified 40 factors necessary for successful control of lym-
phatic filariasis. The most important ones were the initial
level of Wuchereria bancrofti endemicity, the vectorial capacity
of the mosquito vector, the mass drug administration
(MDA) regimen and the population compliance. The authors
identified biological and programmatic factors as the core
drivers (table 1). Here, we detail some of the main issues.
(a) Mapping pathogen distribution
A principal need of any programme is to define the geogra-
phical extent of the problem and define where the public
health problem is greatest. This entails mapping each disease
to provide estimates of the number requiring treatment and
the implementation units and transmission zones. Following
mapping, surveys are required to define baseline epidemiologi-
cal information for sentinel sites, which are essential to follow
progress towards the defined epidemiological endpoints post-
intervention and following a period of intense surveillance to
ensure the endgame scenario has been achieved. The
approaches to mapping for the PC-amenable diseases while
different for each disease are being integrated when possible,
while rapid techniques of assessment of prevalence are avail-
able to define where implementation is required [39,40].
A top priority identified for the African region in order to
accelerate the progress towards elimination of lymphatic filaria-
sis and onchocerciasis [36] is resolving the treatment challenges
posed by the co-endemicity of Loa loa. Ivermectin treatment for
onchocerciasis or lymphatic filariasis given to people with high
parasitaemias of L. loa can result in severe adverse events
(SAEs) [41–43]. Lymphatic filariasis and L. loa co-endemic
areas at high risk of SAEswould benefit by PCwith albendazole
alone (400 mg twice per year) to avoid the use of ivermectin.
Where this is the case, the efforts can be enhanced by reducing
the vector density [44–46]. Recent maps of the distribution of
L. loa produced from the Rapid Assessment Procedure for Loia-
sis [47] and of priority for ivermectin distribution developed
from Rapid Epidemiological Mapping for Onchocerciasis help
identify areas at high risk of SAEs associated with Loa
encephalopathy. For more effective deployment of resources,
endemic areas may require finer scale mapping (e.g. micro-
stratification) [48] to reveal the distribution of various parasites
and also current drug distributions patterns [45] to identify
where alternative intervention strategies are required, likely to
be increasingly crucial as incidence declines. Such approaches
will also reveal potential synergies and benefits, for example
between the lymphatic filariasis elimination and onchocerciasis
control programmes and identify areas where achievement
of endgame objectives can be more easily achieved, and
conversely where additional approaches are required to reach
epidemiological targets.
(b) Assessing coverage
Since the basis of PC resides in the need to ensure sustained
high geographical and therapeutic coverage of the eligible
population over a period of years, knowledge of parasite dis-
tribution and therapeutic coverage achieved in terms of doses
successfully delivered is essential. Geographical coverage is
defined as the proportion of the implementation units of
infected communities which require treatment for diseases
targeted. The calculations of therapeutic coverage in reported
figures are based on the total population in any given setting.
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based distribution can often play an important role in providing
accurate estimates of the true population size for general use by
national authorities. However, in post-conflict countries with
significant disruption of population structure, extensive migra-
tion and resettlement mean estimates of population figures
are necessarily open to question. The WHO provides annual
reports of the total numbers of people treated for each disease
and endemic country [6,7] as well the proportion of those trea-
ted compared within the target population. Parker & Allen
[49,50] have questioned the validity of this reporting on the
basis of studies in Tanzania and Uganda indicating far lower
coverage in some districts than is reported, possibly due to
inadequate social mobilization and health education. These
views were challenged by Molyneux & Malecela [3] based on
the fact that the overall epidemiological results show consistent
impact ofMDA in somany settings. Validation of coverage esti-
mates is desirable, but detailed coverage surveys require an
ongoing commitment of resources that are likely to increase
during the endgame as incidence, prevalence and intensity of
infection fall making monitoring, evaluation and surveillance
on a large-scale both technically and financially challenging.
The need for culturally appropriate and targeted health edu-
cation is essential if the endgame is to be reached within the
timescales of the WHO roadmap targets.(c) Leveraging synergy between different programmes
It has been shown that CDI over 5–6 years with 65 per cent or
more coverage could significantly reduce the prevalence and
intensity of other filarial parasites, mainly W. bancrofti [51,52]
and some soil-transmitted helminthiases [53,54]. Similarly,
repeated doses of albendazole used in soil-transmitted hel-
minthiasis programmes, particularly for school-aged children,
could potentially impact on W. bancrofti prevalence. Equally,
the scale up of lymphatic filariasis elimination programmes
using ivermectin and albendazole across large regions of Africa
could help to reinforce the achievements of onchocerciasis con-
trol. This would assist in reducing the potential residual human
reservoir population of O. volvulus and preventing introduction
into areas where the disease has been eliminated. In Haiti, the
widespread distribution of albendazolewithin lymphatic filaria-
sis programmes reduced the prevalence and intensity of soil-
transmitted helminths, including Ascaris lumbricoides, Trichuris
trichiura and hookworm [53]. However, in contrast to Sri
Lanka, Gunawardena et al. [55] showed limited and non-signifi-
cant changes in prevalence in school-aged children examined
although the compliance reported was only 59 per cent. In Zan-
zibar, Mohammed et al. [54] examined records from 50 health
centres over a 6-year period starting prior to the initiation of
MDA for lymphatic filariasis, and recorded that the impact of
PC was a dramatic decline in both reported cases and required
treatments for worm infections and scabies. Harnessing these
types of synergies may be important during the endgame
where interest in treatment for infections whose rarity makes
them seem negligible wanes.(d) Reaching populations
(i) Elimination and remote and migrant populations
Despite the progress towards the elimination of onchocerciasis
in the Americas, some foci still remain, for example recently
discovered newly infected communities in the Amazon.These communities are mobile, making the endgame in such
inaccessible environments a serious challenge not just in initiat-
ing treatment but also in monitoring and post-treatment
surveillance. Of the six countries where onchocerciasis was
endemic, transmission remains ongoing in foci in the
Amazon rainforest on the border between Venezuela and
Brazil where there is limited access, making the indigenous
Yanomami populations ones who are most at risk [56]. The
major challenge is ensuring high coverage ivermectin treat-
ment four times a year to mobile populations who live in
most inaccessible areas. Alternatively, given the goal to stop
transmission in the Americas by 2015, the newly discovered
infected communities could be treated with doxycylcine
whichmight be themost effectiveway to achieve the endgame.(e) Urban disease elimination
In contrast to onchocerciasis, lymphatic filariasis and schisto-
somiasis are transmitted in urban settings [57], providing a
different set of challenges for organization of drug distribution
campaigns. In large cities such as Dar es Salaam, Lagos or
Accra, where the population exceeds several million people,
reaching a high coverage is both difficult and costly. The
major vector of W. bancrofti in East African urban settings
such as Dar es Salaam is Culex, while Culex appears not to
be susceptible to W. bancrofti in West African cities [58]. Culex
control in urban areas is difficult; hence the achievement
of the endgame in Dar es Salaam, for example, will be a
challenge as vector control of larval habitats cannot be success-
fully deployed on sufficient scale. By contrast, Anopheles gambiae
and Anopheles funestus are the dominant rural vectors of
W. bancrofti [59] whose control will be enhanced by use
of impregnated bednets, with the effect of reducing duration
of MDA required during the endgame.
Overall, the lymphatic filariasis endgame scenario will be
determined by the vectorial capacity of the dominant vector (or
in West Africa the lack of susceptibility of Culex), the coverage
andduration ofMDA, the extent of the deployment of insecticide
impregnated bednets or long-lasting impregnated nets (LLINs)
for malaria control, and, if feasible, the use of a macrofilaricidal
drug the most promising being doxycycline [60,61]. In addition,
the impact ofmigration fromrural areas to cities inAfricawill bea
factor in driving the urban prevalence given the extensive preva-
lence observed in mapping studies in rural areas [62–64]. This
presents a dilemma in deciding a treatment strategy if there is
no active urban transmission. The complexity of urban environ-
ments in terms of transient populations, and areas where there
are immigrants fromdifferent rural localities, provides challenges
in dealing with this heterogeneity in terms of sampling, access
and the costs of any evaluation and surveillance activities.
The problems of urban transmission and endgame scenarios
are also applicable to schistosomiasis. Recent studies in Cote
d’Ivoire, Nigeria andZambia have all highlighted the challenges
of both S.mansoni andS. haematobium transmission in peri-urban
and urban settings [57,65,66]. However, there will be persistent
problems of soil-transmitted helminthiasis morbidity in urban
and peri-urban areas because of deficient water and sanitation.
Therefore, treatment of urban populations of school-aged chil-
dren with anti-helminthics will be required until the water and
sanitation services are sufficiently robust and sustained in paral-
lel with reinforced efforts to change behaviour. A problem in
peri-urban settings is the extensive use of human faecal material
(night soil) contaminated with helminth eggs as a fertilizer for
rstb.
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In Asia, schistosomiasis is caused predominantly by S. japoni-
cum, a zoonosis. Some 40 mammalian species are hosts
although only 10 are considered to contribute to transmission
to humans [67]. This situation requires a more integrated
approach to control as PC alone cannot lead to elimination.
In China, where the principal reservoir hosts are cattle and
water buffalo, Wang et al. [68] have described the measures
used to reduce transmission which include chemotherapy
with praziquantel, removal of water buffalo from snail-
infected grasslands and their replacement with mechanized
farm equipment, improving sanitation and the implemen-
tation of an intensive health education programme. In
addition to other measures, there is the prospect of vaccinat-
ing water buffalo and cattle with an anti-schistosome vaccine
[69]. However, additional animal reservoirs—dogs, rodents,
sheep and pigs—which cannot be targeted for control make
this strategy inapplicable for the other Asian schistosome of
humans (S. mekongi found in Cambodia and south Lao
PDR [27,67]) and in the Philippines. There are no animal
reservoirs of onchocerciasis or lymphatic filariasis caused
by W. bancrofti.(g) Vector control and integrated vector management
A key factor that commonly determines outcomes of NTD
control is the initial efficiency and abundance of the vector
populations. Permanent elimination appears to have been
possible in the case of onchocerciasis, where vector popu-
lations are isolated. On the island of Bioko, in Equatorial
Guinea, the vector, a specific form of Simulium yahense [70],
was eliminated by helicopter larviciding. In Uganda, the
vector Simulium neavei in the isolated Itwara focus [71] was
controlled by ground larviciding with temephos, starting in
1995. Previously, control efforts had been annual CDIwith iver-
mectin, but after 4 years, transmissionwas still considerable; the
number of infective bites per year was estimated to be 4500–
6500, and 40 per cent of parous flies S. neavei harboured devel-
oping O. volvulus larvae. The impact of the vector control in
Itwara was monitored by the examination of the crab popu-
lation for the larvae of S. neavei, which have a phoretic
association with a particular crab Potamonautes aloysiisabaudiae.
Transmission appears to have been halted in 2001 and no
infested crabs have been found since 2003 by vector control [71].
For more widespread vector populations, significant
impacts on multiple NTDs can be achieved via vector control
[72], particularly in the context of malaria control programmes.
Huge numbers of insecticide-treated nets (ITNs) and LLINs
have been distributed as part of malaria control efforts,
which has reduced the prevalence of W. bancrofti and led to
elimination or near elimination of transmission in the Solomon
Islands [73]. Similar impacts on other NTDs have also been
observed in Nigeria [74], Kenya and Uganda [75,76] and in
high transmission areas of PapuaNewGuinea [77,78]. Bockarie
et al. [44] and van den Berg et al. [45] argue that vector control
can supplement MDA and foreshorten the need for MDA
given the impact of vector control on transmission parameters
such as annual biting rates and annual transmission potentials.Vector control targeting Anopheles is largely dependent on
synthetic pyrethroids, the single insecticide recommended for
net impregnation and the dominant insecticide class used for
indoor residual spraying (IRS). However, resistance to pyre-
throids is already widespread in parts of West and Southern
Africa [79,80]. To increase insecticide choice for IRS, the orga-
nochlorine dichlorodiphenyltrichloroethane (DDT) has been
re-introduced, following almost three decades of suspended
use [81] due to resistance affecting more than 50 species of
Anopheles [82]. Alarmingly, DDT resistance has re-emerged in
West Africa and was recently detected as far south as
Zambia [83]. Resistance may already signify operational sig-
nificance for the rollout of LLINs for malaria control and is
likely to become a serious impediment to the objectives of
malaria control or elimination in coming years.
At present, the use of either pyrethroids in bednets or IRS
with any single insecticide is effectively a ‘monotherapy’.
Evolution is a powerful opponent, and history suggests
that insecticide monotherapy is likely to fail, as does chemo-
therapeutic monotherapy. Unfortunately, few cost-effective
alternative insecticides currently exist. LLIN efficacy is thus
likely to decline as pyrethroid resistance spreads, potentially
approaching the minimal levels of low benefit provided by un-
impregnated bednets as shown by studies in Papua New
Guinea [78]. Consequently, there is likely to be a limited
window of opportunity for the lymphatic filariasis programmes
to benefit from ITNs/LLINs [45,84] via integrated vector
management, particularly in the context of the endgame.(h) Coverage and compliance: social mobilization
The challenge as the endgame approaches is the maintenance
of community enthusiasm for delivering drugs. Current pro-
blems are that incentives are provided by other programmes
and the pressure on ‘volunteers’ to deliver other health inter-
ventions [14]. The issue of providing a form of remuneration
is an ongoing debate, but one that may impact on the ability
of PC interventions to achieve the requisite coverage over the
years needed to achieve the endgame scenarios. Training of
community workers, social mobilization and information,
education and communication (which is often locally specific)
are continuing costs to programmes, and require the attribution
of adequate resources as a proportion of health budgets.
There is also a need to seek to reduce the attrition of commu-
nity distributors given the investment in their training and
the value of their role in the community. Studies clearly
demonstrate that should coverage fall below 65 per cent—the
estimated level of the total population—it is likely that the
MDA annual cycles will need to be extended for several
years to achieve the requisite endpoints in both lymphatic
filariasis and onchocerciasis [13,85].
Compliance is also important and should be differen-
tiated from coverage. Compliance refers to the frequency
with which individuals comply to take the provided drugs,
and usually only a proportion of the eligible population are
found to have complied with all treatment rounds. It has
also been found that there are systematic non-compliers
who will thus remain a source of continued infection. Identi-
fying systematic non-compliance and reinforcing the value of
compliance within the social mobilization and health edu-
cation activities at the community level is critical if the
criteria for cessation of MDA are to be achieved.
rstb.royalsocietypublishing.org
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thresholds of prevalence of infection remain valid for achieving
control of schistosomiasis-associated morbidity and achieving
elimination of schistosomiasis as a public health problem,
a more intensified strategy is required in areas where the
aim is that of interrupting transmission, which may include
more frequent treatment or even focal mollusciciding using
‘niclosamide’ [86]. An integrated approach is required through
enhanced efforts to promote behaviour change as well as
increased provision of clean water and improved sanitation.
The WHO [7] sets out the details of the goals, interventions,
targets and the timeline for schistosomiasis elimination
towards 2020while Rollinson et al. [25] discuss the background
and challenges the elimination agenda presents, in particular
the lessons from previous successes and the options that the
goal of elimination presents in the many different settings.
(i) Exclusion criteria
Most drugs used in PC have exclusion criteria, including preg-
nancy (all drugs), age (children under 2 years for albendazole;
less than 90 cm in height for ivermectin as a surrogate for less
than 5 years; and less than 94 cm for praziquantel) and the very
sick. Clearly, this leaves behind a potential untreated human
reservoir for the pathogen, beyond that which simply results
from poor coverage (i.e. if treatment is via school, coverage
may be low because not all children attend schools).
For schistosomiasis, there is evidence that pre-school-
aged children in highly endemic areas are at risk of schistoso-
miasis infection (a study in Uganda that used parasitological
examination of stools and urine dipsticks found prevalences
between 32 and 40 per cent [87]), but they are not targeted
by MDA. Rather, the WHO currently recommends that chil-
dren under 4 years of age be treated individually in health
facilities as part of the national control programme [88].
This is because there is currently no appropriate formulation
of praziquantel to administer to this age group.
( j) Future drug improvement, drug resistance and
the endgame
Ivermectin has been an exceptionally valuable public health
product for lymphatic filariasis and onchocerciasis control/
elimination allied to albendazole and DEC for lymphatic
filariasis, but elimination programmes could be dramatically
foreshortened by a drug which kills adult worms. The most
exciting prospect lies in the proven macrofilaricidal efficacy
and sterilizing effect of the antibiotic doxycycline which tar-
gets the obligatory endosymbiont, Wolbachia, present in
many filarial parasites [61]. If given over a period of four
weeks, doxycycline will kill or permanently sterilize adult
Onchocerca and Wuchereria [22,60], but children under
9 years old and pregnant women are ineligible for treatment,
and hence are a potential reservoir. Community studies
demonstrate not only efficacy but a high level of compliance
to programmes involving this treatment [89]. There are
ongoing studies to reduce the duration of treatment and
search for alternative antibiotics that target the symbiont
Wolbachia [61], as this approach to elimination holds promise
where the community-directed approach with ivermectin has
been less effective and where there may be a potential loss of
efficacy or true resistance [90]. Doxycycline or similar anti-
Wolbachia antibiotics provide tools of considerable value inachieving the endgame of killing or sterilizing adult worms
and the epidemiological endpoint for both lymphatic filaria-
sis and onchocerciasis. To address the endgame challenges
among onchocerciasis foci in Venezuela and Brazil, macrofi-
laricidal treatment (test and treat with a six-week course of
doxycycline 100 mg per day, which kills adult parasites) is
being considered to overcome the limitations of ivermectin.5. Resources: financial, human capacity and
country commitment
A constraint in any health programme is that only finite
resources are available. The NTDs are no exception, and pro-
grammes are constrained by the lack of available resources
despite availability of the donated drugs. Recently, the
USAID and the UKDFID significantly increased their commit-
ments to the control and elimination of these diseases as stated
in the London Declaration (www.unitingtocombatntds.org).
The Bill & Melinda Gates Foundation committed US$
340 million over the coming 5 years to support research into
NTDs. NGDOs continue to raise finance for implementation
of country programmes in onchocerciasis, lymphatic filariasis
and trachoma. Increasing recognition by endemic countries is
needed to incorporate NTD control into national health
plans, budgets and poverty reduction strategies to ensure sus-
tainable finance. The APOC programme continues to enjoy
support from a consortium of donors and has been able to sup-
port NTDprogrammes in countries endemic for onchocerciasis
since 2006. The annual APOC budget of aroundUS$ 20 million
is administered through a World Bank Trust Fund, and bilat-
eral donors have committed to support the new objective
of elimination of onchocerciasis financially until 2015. The
bilateral support from the USAID is directed to ensuring that
integrated NTD programmes are initiated in selected endemic
countries, with countries themselves contributing a proportion
of the costs of programmes through provision for example of
staff, office and laboratory facilities.
A particular need in NTDs and a challenge for the expan-
sion of future programmes is the availability of human
resource capacity. Throughout the domain of global health,
the lack of human resources at all levels of the health sys-
tems in poorer countries is recognized as a barrier to a better
functioning of health services. Notwithstanding potential
technical (reduced efficacy of drugs), political (conflict or civil
unrest) and environmental (global climate impacts) challenges,
without the requisite country skills from the central level to the
community, no programme can effectively function and this
needs to be addressed as a priority. The process of identifying
the barriers to enhanced capacity strengthening requires a situ-
ation analysis with stakeholders to provide a basis for future
planning to deliver the human resources to deliver the end-
game of elimination. Two essential issues emerge: research
capacity [91,92] and implementation capacity [7]. The need
for implementation capacity will drive the achievement of
the WHO roadmap targets. However, the research training is
required within endemic as well as developed countries’ aca-
demia and research institutions that focus on the search for
new tools. However, the priority must be to enhance the
capacity needed to implement the existing tools to achieve
further scale up of PC and associated morbidity control (e.g.
surgery for trachoma and lymphatic filariasis). There must
also be the recognition that timelines to deployment of tools
rstb.royalso
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should be introduced into practice as soon as safe and practic-
able. Too often there are significant delays in translating
research findings into practice. Such delays can postpone the
achievement of the endgame for several diseases. cietypublishing.org
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We have identified the challenges to the implementation of
PC programmes to control or eliminate diseases responsible
for a significant health burden in some of the world’s poorest
countries. PC is based on efficacious drugs, the majority of
which are donated and provided on a long-term basis by sev-
eral major pharmaceutical companies—some ‘as long as
needed’. A significant increase in the number of treatments
has been achieved over recent years with over 700 million
people receiving the necessary drugs each year [7]. However,
to achieve the goals set by WHA resolutions (see the elec-
tronic supplementary material, table S1) and the endpoints
identified in the WHO roadmap, the further commitment
of resources will be required to achieve the target annual
treatment of at least one billion for the coming 5–10 years [7].
The increasing use of donated drugs when dealing with
a single strategy of control or elimination for diseases in
different regional settings creates significant complexity
both technically and from a policy perspective. To ensure
that endemic countries have a central role in all aspects of
these programmes, there should be coordination and com-
munication among the partnership involved in financing,
implementation, research and health policy.The challenges of partnership, resourcing and com-
munication are not unique to NTDs nor are the particular
challenges of up scaling to ensure the necessary geographical
coverage and timely implementation of annual distribution.
Given that the drugs used in these programmes have syner-
gistic impacts, there becomes an increasing complexity in
analysing the impact of programmes. Evaluation and moni-
toring to ensure post-control surveillance is critical, and will
require additional financing.
There must be a continuous emphasis on improving
the efficiency of the PC strategy, by developing improved
monitoring and surveillance tools, seeking alternative drugs
in the event of loss of efficacy or resistance, ensuring effective
reporting systems and maintaining as high a coverage as
possible. Approaches to ensuring sustained high coverage
often over many years will need health education program-
mes to fit local social and cultural settings. At the global
policy level, the challenge of ensuring that continued bilateral
funding is available, through an emphasis on the key advo-
cacy messages about the impact of these diseases as drivers
of poverty and our ability through highly cost-effective inter-
ventions to reduce the burden or even eliminate them, is
critical. High profile advocates will remain an important
means of emphasizing that investment in NTD control and
elimination is a major contribution to poverty alleviation.
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